A phase I clinical trial (NCT05105971) in patients with advanced cancer (n=30) showed that OX40 agonist BAT6026 0.01-10mg/kg monotherapy had a good safety profile, and immune-related adverse events were grade 1-2, distributed in different dose groups, mainly rash (131). The gene discussed is TNFRSF4; the disease is cancer.